0001209191-22-017696.txt : 20220309 0001209191-22-017696.hdr.sgml : 20220309 20220309190012 ACCESSION NUMBER: 0001209191-22-017696 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220307 FILED AS OF DATE: 20220309 DATE AS OF CHANGE: 20220309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROBINS CHAD M CENTRAL INDEX KEY: 0001780649 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 22726839 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-07 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780649 ROBINS CHAD M C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1165 EASTLAKE AVENUE E SEATTLE WA 98109 1 1 0 0 CEO and Chairman Common Stock 2022-03-07 4 M 0 14815 6.32 A 1930969 D Common Stock 2022-03-07 4 S 0 500 12.22 D 1930469 D Common Stock 2022-03-07 4 S 0 14315 11.53 D 1916154 D Common Stock 2022-03-08 4 M 0 14815 6.32 D 1930969 D Common Stock 2022-03-08 4 S 0 14815 11.38 D 1916154 D Common Stock 2022-03-09 4 M 0 14815 6.32 D 1930969 D Common Stock 2022-03-09 4 S 0 14815 12.46 D 1916154 D Stock Option (Right to Buy) 6.32 2022-03-07 4 M 0 14815 0.00 D 2025-06-09 Common Stock 14815 785185 D Stock Option (Right to Buy) 6.32 2022-03-08 4 M 0 14815 0.00 D 2025-06-09 Common Stock 14815 770370 D Stock Option (Right to Buy) 6.32 2022-03-09 4 M 0 14815 0.00 D 2025-06-09 Common Stock 14815 755555 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2021. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $12.21 to 12.24, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.21 to 12.20, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.27 to 11.55, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $12.21 to 12.73, inclusive. The option is fully vested and exercisable. /s/ Chad Robins by Eric Billings, Attorney-in-Fact 2022-03-09